EXTH-13. REDUCTION OF TUMOR BURDEN AND HEARING LOSS WITH A MULTIPLE RECEPTOR TYROSINE KINASE INHIBITOR BRIGATINIB IN A GENETICALLY ENGINEERED MOUSE MODEL OF NEUROFIBROMATOSIS TYPE 2

Neurofibromatosis Type 2 (NF2) is an autosomal dominant genetic disorder caused by germline mutations in the tumor suppressor gene NF2, which encodes the protein Merlin. Patients with NF2 may develop bilateral vestibular schwannomas, which cause hearing impairment, and schwannomas in other regions of the nervous system. Due to the nature and location of the tumors, there is high morbidity and mortality associated with NF2, and no known effective...